Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 7/20 | 0.45 |
| ▸ | SFRP1 | Q8N474 | 11/20 | 0.43 |
| ▸ | WNT3 | P56703 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6099337 | 0.89 | USP30 (0.45) | HTR6SFRP1WNT3ALDH1A1PKM | |
| SCHEMBL6102761 | 0.86 | GHSR (0.41) | SFRP1WNT3 | |
| SCHEMBL6102759 | 0.86 | GHSR (0.41) | SFRP1WNT3 | |
| SCHEMBL4616096 | 0.84 | SFRP1 (0.49) | SFRP1WNT3ALDH1A1 | |
| SCHEMBL6103313 | 0.83 | HTR1A (0.42) | HTR6SFRP1WNT3 | |
| SCHEMBL4618208 | 0.82 | SFRP1 (0.50) | SFRP1WNT3ALDH1A1LMNA | |
| SCHEMBL4616617 | 0.82 | SFRP1 (0.41) | SFRP1WNT3ALDH1A1LMNA | |
| SCHEMBL6101132 | 0.82 | SFRP1 (0.39) | SFRP1WNT3KDM4EALDH1A1LMNA | |
| SCHEMBL6102915 | 0.81 | SFRP1 (0.45) | SFRP1WNT3KDM4EALDH1A1 | |
| SCHEMBL6103663 | 0.80 | SFRP1 (0.35) | SFRP1WNT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | claimed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | claimed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | claimed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | HTR6 3789/4885SFRP1 1/4885WNT3 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.